Full-Time

Associate Director, Manufacturing Science and Technology

Manufacturing Science and Technology

AskBio

AskBio

501-1,000 employees

Clinical-stage gene therapy company developing AAVs

No salary listed

Durham, NC, USA

In Person

Category
Biology & Biotech (1)
Requirements
  • Bachelor’s degree in a scientific or engineering discipline and 10+ years of relevant experience OR Master’s Degree in a relevant scientific or Engineering field and 8+ years of experience
  • Significant experience in Upstream and/or Downstream biomanufacturing including aspects such as materials selection and qualification, cell bank management, bioreactors, harvest, recovery, filtration, process analytics. Experience should span platform development, technology transfer, Process Validation, and commercial process monitoring.
  • Experience leading one or more PPQ/Process Validation campaigns including preparation and execution, validation master plans, risk assessments, protocols and reports.
  • Proficiency with statistical analysis software such as JMP
  • Knowledge of US and international regulatory standards and ICH guidelines and substantial experience authoring and/or contributing to regulatory submissions.
  • Significant regulatory inspection experience as an SME, or contributor.
  • Excellent written and verbal communication skills with the ability to communicate effectively across a number of disciplines and experience levels.
  • Strong attention to detail, highly organized and the ability to multitask in a fast-paced, highly interactive environment.
  • Proven track record of leading cross-functional collaborations to improve business processes.
  • Able to travel, domestic and international, up to ~10%
Responsibilities
  • Mentor and guide cross-functional team(s) on all aspects of technology transfer of gene therapy processes from process development into the MSAT laboratory and then into cGMP production
  • Use your knowledge of the Design of experiment (DOE) methodology to design optimization programs and guide teams as they manage process optimization campaigns
  • Develop a strategy for a risk-based small-scale model development campaign that is predictive of manufacturing and enables process characterization.
  • Mentor teams on the development of a risk-based process characterization campaign that maximizes the value of study results to support a PPQ-ready process control strategy.
  • Lead the PPQ/Process Validation campaign for an AskBio gene therapy product including preparation of validation master plans, risk assessments, protocols and reports. Provide oversight of PPQ and Process Validation execution.
  • Lead the development of a Continuous Process Verification plan for an AskBio gene therapy product including establishing trending, and annual reporting systems.
  • Use your upstream and/or downstream biomanufacturing experience and technical understanding of cGMP manufacturing operations to design and guide continuous improvement projects, in partnership with process development and external manufacturing in order to improve manufacturability, reliability, yield and cost.
  • Support equipment and reagent supplier technical evaluations, risk assessments, and raw material evaluation and qualification.
  • Set standards for technical protocols and reports to support experimental work while ensuring your team maintains organized electronic laboratory notebooks.
  • Review and approve documents and ensure suites of documents are suitably aligned.
  • Provide effective and persuasive communication of experimental results in technical presentations with internal and external stakeholders including communication to senior leadership, corporate functions, and external parties.
  • Set standards for, and give technical oversight of investigations into process deviations by employing robust quality risk management methodologies to guide resolution and implement corrective actions by leveraging a data-driven approach.
  • Design and establish sustainable CAPAs as needed.
  • Ensure the laboratory is clean, organized and maintained in an efficient and working order.
  • Ensure supplies and materials for experiments are properly planned and support proper scheduling of laboratory work.
Desired Qualifications
  • Prior experience in manufacturing technology of gene therapy products is strongly preferred.
  • Prior CMC experience with pre-approval and post-approval activities for a biologic or gene therapy product
  • Experience developing or leading a Continuous Process Verification Campaign including trending, and annual product life cycle monitoring and reporting with biologic or gene therapy products
  • Prior experience and / or certification in a continuous improvement methodology (e.g. Six Sigma)
  • Experience using data management systems, analysis, and reporting tools

AskBio focuses on developing adeno-associated virus (AAV) gene therapies for genetic and complex disorders. Therapies use AAV vectors to deliver therapeutic DNA into patients’ cells, advancing from research and preclinical work through clinical trials toward commercialization. Its differentiation comes from a clinical-stage portfolio, in-house R&D, and partnerships that emphasize collaboration and shared development. Its goal is to bring gene therapies to patients with unmet medical needs by validating therapies clinically and pursuing strategic collaborations for commercialization.

Company Size

501-1,000

Company Stage

Acquired

Total Funding

$4.2B

Headquarters

Durham, North Carolina

Founded

2001

Simplify Jobs

Simplify's Take

What believers are saying

  • Bayer ownership funds global facilities in RTP, Edinburgh, and San Sebastian.
  • Phase 2 GenePHIT trial for AB-1002 completes enrollment in 2026.
  • Licenses to Pfizer, Takeda, Novartis validate platform technology.

What critics are saying

  • GenePHIT trial fails primary endpoint, halts AB-1002 program.
  • AB-1005 Phase 2 shows no GDNF increase, cancels Parkinson's advancement.
  • Bayer divests AskBio after clinical failures within 18-24 months.

What makes AskBio unique

  • AskBio pioneers AAV gene therapies with Pro10 manufacturing and extensive capsid library.
  • Founders' research underpins first two FDA-approved gene therapies.
  • Pipeline targets heart failure, Parkinson's, MSA-P, Pompe, and Huntington’s diseases.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at AskBio who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Profit Sharing

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Pet Insurance

Bereavement Leave

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Wellness Program

Mental Health Support

Gym Membership

Commuter Benefits

Meal Benefits

Phone/Internet Stipend

Home Office Stipend

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
Pharma Press
Mar 25th, 2026
a-Klotho cell and gene therapy potential.

a-Klotho cell and gene therapy potential. 25 March 2026 Avaí Bio recently announced that it has initiated manufacturing of a master cell bank of genetically modified cells that overexpress the α-Klotho protein, working alongside joint venture partner Austrianova through their shared entity, Klothonova. A Master Cell Bank isn't a research milestone. It's a manufacturing milestone. It's the GMP-compliant, fully characterized starting material from which all working cell banks and final therapeutic products will be produced. It's the moment a cell therapy programme transitions from "we think this could work" to "we're building the production infrastructure to deliver it." There is a key 'master' protein in your body called α-Klotho. The scientific community has been quietly obsessed with it since a Japanese researcher named Makoto Kuro-O discovered in 1997 that mice without the Klotho gene aged rapidly and died young - and mice with extra Klotho lived 30% longer. Since then, the research has only gotten more compelling. Peer-reviewed studies have linked higher Klotho levels to reduced risk of Alzheimer's, certain cancers, cardiovascular disease, and kidney failure. Mayo Clinic research has connected declining Klotho to arterial stiffness and vascular calcification. And here's the part that makes this personal: natural α-Klotho levels drop by approximately 50% after age 40. The protein that protects your brain, your heart, and your kidneys starts disappearing right when you need it most. The question the biotech industry is now racing to answer is simple: can you put it back? The global cell therapy market has surpassed $8.2 billion in 2026. The broader cell and gene therapy sector is forecast to surge from $10.4 billion to more than $45 billion by 2035. And at the intersection of regenerative medicine and longevity science, a small biotechnology company just hit a manufacturing milestone that turns the Klotho thesis from laboratory theory into production reality. The Cell-in-a-Box(R) technology is the delivery mechanism that makes the whole approach viable. When you transplant therapeutic cells into a patient, the immune system typically destroys them within days. Austrianova's encapsulation technology protects the cells inside a porous capsule, allowing the cells to continuously produce and secrete the target protein - in this case, α-Klotho - while protecting the cells from immune rejection. It's backed by over 50 peer-reviewed publications and decades of development. Avaí Bio's dual-programme approach targets both the Klothonova anti-aging platform and the Insulinova diabetes program, each leveraging the same Cell-in-a-Box(R) encapsulation technology. The addressable markets are enormous: Alzheimer's disease alone is projected to reach $32.8 billion by 2033, cardiovascular disease remains the leading cause of death globally, and kidney disease affects 850 million people worldwide.

ChemXpert
Apr 3rd, 2025
Bayer Heralds Pipeline Progress, Blockbuster Launches and Advanced

Through AskBio, a wholly owned subsidiary of Bayer, it is developing a gene therapy as a potential new approach for treating congestive heart failure.

AskBio
Nov 5th, 2024
Brain Neurotherapy Bio | AskBio

Brain Neurotherapy Bio, Inc (BNB) is pleased to announce its recent merger with Asklepios BioPharmaceutical, Inc (AskBio), a Bayer company.

BambuUP
Sep 25th, 2024
Belief BioMed to Collaborate with AskBio to Explore the Potential of New Gene Therapies

Belief BioMed to collaborate with AskBio to explore the potential of new gene therapies.

The Business Journals
Apr 9th, 2024
AskBio co-founder Jude Samulski steps down, successor named

As it advances its pipeline of gene therapies, AskBio is planning to expand in the Triangle, essentially doubling its local footprint by acquiring space in Morrisville on Airport Road.